Name | Indication |
---|---|
Lonsurf | To treat adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and an anti-EGFR therapy |
Kadcyla | To treat (adult) patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane |
Xofigo | To treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs |
Inlyta | To treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer |
Perjeta | To treat patients with HER2-positive late-stage (metastatic) breast cancer in combination with Herceptin and docetaxel |
Xtandi | To treat men with late-stage (metastatic) castration-resistant prostate cancer who have received docetaxel therapy |
Zytiga | In combination with prednisone (a steroid) to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy) |